Skip to main content

Table 3 Patient demographics and baseline clinical characteristics

From: High-dose interleukin2 – a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome

 

Number (%)

Pre-selection N = 30

Post-selection N = 115

Overall N = 145

Age (median)

19–68 (52)

28–77 (54)

19–77 (54)

Male

23 (76.7)

82 (71.3)

105 (72.4)

Nephrectomy

26 (86.7)

115 (100)

141 (97.2)

MSKCC risk

 Good

19 (63.3)

98 (85.2)

117 (80.7)

 Intermediate

11 (36.7)

17 (14.8)

28 (19.3)

 Poor

0

0

0

Heng risk

 Favourable

7 (23.3)

60 (52.2)

67 (46.2)

 Intermediate

19 (63.3)

47 (40.9)

66 (45.5)

 Poor

4 (13.3)

8 (6.9)

12 (8.3)

Pathology type

 Favourable

17 (56.7)

106 (92.2)

123 (84.8)

 Other

13 (43.3)

9 (7.8)

22 (15.2)

No of met organ(s)

 1

10 (33.3)

42 (36.5)

52 (35.9)

 2

7 (23.3)

41 (35.7)

48 (33.1)

 3 +

13 (43.3)

32 (27.8)

45 (31.0)